# 🧾 What This Document Is This is an 8-K filing from Sangamo Therapeutics, a biotech company. It includes a press release (Exhibit 99.1) that serves as their official update to the market. Think of it as a "state of the union" report, detailing their recent scientific progress and financial health

Read summaryView on SEC EDGAR

SEC filings

All filings →

1 recent filing shown in the timeline above. View all SEC filings →

Insider trades

All insider trades →

SGMO has no reported insider trades in the last 90 days.

Institutional holders

All holders →

As of 2025-12-31 · prior 2025-09-30

RENAISSANCE TECHNOLOGIES LLC$3.5M

8,430,323 sh-17.2%

VANGUARD GROUP INC$5.0M

12,000,383 sh+3.3%

SUSQUEHANNA INTERNATIONAL GROUP, LLP$1.3M

3,155,520 sh-15.8%

BlackRock, Inc.$1.9M

4,571,786 sh+0.3%

CITADEL ADVISORS LLC$188,160

448,000 sh-73.5%

GEODE CAPITAL MANAGEMENT, LLC$1.6M

3,866,026 sh+17.6%

UBS Group AG$430,280

1,024,475 sh-22.4%

TWO SIGMA ADVISERS, LP$1.8M

4,343,255 sh+106.0%

People at SGMO

Dubois-Stringfellow Nathalie

Quarterly financials

Full financials →

Revenue trend

03/25

—

NI -$30.6M

06/25

—

NI -$20.0M

09/25

$581.0K

NI -$34.9M

RevenueNI = Net Income

EPS trend (diluted)

Latest: $-0.11

Prior: $-0.08

Revenue sparkline